Acrivon Therapeutics (ACRV) Other Non-Current Assets (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Other Non-Current Assets of $1.5 million for Q1 2026, down 8.32% year-over-year from $1.6 million in Q1 2025, and down 8.65% quarter-over-quarter from $1.7 million in Q4 2025.
Acrivon Therapeutics (ACRV) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Other Non-Current Assets for 6 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 8.32% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 8.32% YoY), while the FY2025 annual figure was $1.7 million, changed 0.36% from the prior year.
- Other Non-Current Assets retreated to $1.5 million in Q1 2026 per ACRV's latest filing, from $1.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.7 million in Q4 2025 and bottomed at $196000.0 in Q3 2024.
- Historically, Other Non-Current Assets has averaged $878800.0 across 5 years, with a median of $417000.0 in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets tumbled 52.31% — and 2025, when it surged 740.31%.
- Acrivon Therapeutics' Other Non-Current Assets stood at $388000.0 in 2022, then advanced by 6.7% to $414000.0 in 2023, then jumped by 297.83% to $1.6 million in 2024, then rose by 0.36% to $1.7 million in 2025, then slipped by 8.65% to $1.5 million in 2026.
- Business Quant data shows ACRV's Other Non-Current Assets at $1.5 million in Q1 2026, $1.7 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 1.65 Mn |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | 1.65 Mn |
| Mar 31, 2025 | 1.65 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Sep 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 421,000.00 |
| Mar 31, 2024 | 417,000.00 |
| Dec 31, 2023 | 414,000.00 |
| Sep 30, 2023 | 411,000.00 |
| Jun 30, 2023 | 408,000.00 |
| Mar 31, 2023 | 388,000.00 |
| Dec 31, 2022 | 388,000.00 |
| Sep 30, 2022 | 388,000.00 |
| Dec 31, 2021 | 388,000.00 |